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Raquel Villarb, Beatriz Solanob, Elsa Morenob, Enrique Torresb, Silvia Pérezb, Ignacio 
Aldanab, Antonio Mongeb. 
We report the synthesis, anti-inflammatory and antioxidant activities of novel 
quinoxaline and quinoxaline 1,4-di-N-oxide derivatives. Microwave assisted 
methods have been used in order to optimize reaction times and to improve the 
yields. The tested compounds presented important scavenging activities and 
promising in vitro inhibition of soybean lipoxygenase. Two of the best 
lipoxygenase inhibitors (compounds 7b and 8f) were evaluated as in vivo anti-
inflammatory agents using the carrageenin-induced edema model. One of them 
(compound 7b) showed important in vivo anti-inflammatory effect (41%) similar 
to that of indomethacin (47%) used as the reference drug.  
Introduction 
Arachidonic acid (AA) metabolism, mediated by the LOX enzyme family, leads to the generation of leukotrienes, 
a type of pro-inflammatory mediators, that are involved in processes such as fever, asthma1 or cardiovascular 
disease.2Aberrant AA metabolism is also related to carcinogenesis. In that respect, recent studies revealed increased 
LOX expression levels in a wide range of cancers including pancreatic, bladder or breast cancer.3-5
On the other hand, during the inflammation process, phagocytic leukocytes (e.g. neutrophils, monocytes, 
macrophages, eosinophils) produce reactive oxygen species (ROS), such as superoxide radical anion, hydrogen 
peroxide and hydroxyl radical. The presence of high levels of ROS induce and heighten certain pathological 
conditions such as carcinogenesis, atherosclerosis and neurodegenerative diseases6-8 and are well known to be 
involved in the induction and prolongation of inflammatory process.9,10 The involvement of ROS in inflammation is 
confirmed by a number of commercially available non-steroidal anti-inflammatory drugs NSAIDs (acetaminophen, 
salicylates, indomethacin and nimesulide) that have been demonstrated to possess radical scavenging properties.11-14 
Taking into account the above mentioned relationship between ROS and inflammation as well as the importance of 
inhibition of LOX to combat inflammatory and carcinogenic processes, the development of new compounds having 
both anti-inflammatory and antioxidant activities and being LOX inhibitors constitutes an interesting approach in the 
obtention of new drugs for cancer prevention, treatment of chronic inflammation and other related pathological 
conditions. 
Quinoxaline 1,4-di-N-oxide derivatives are a class of compounds having a great interest in medicinal chemistry as 
they display a broad range of biological properties such as antibacterial, anticancer or antiparasitic.15-17 We have 
demonstrate18 that quinoxaline 1,4-di-N-oxide derivatives show also very interesting antioxidant and anti-
inflammatory properties, some of them displaying an in vivo anti-inflammatory effect higher than the reference drug, 
indomethacin IMA, and promising in vitro inhibition values of LOX (<1μM). 
Based on these results and with the aim of obtaining new compounds with improved activities we now describe the 
synthesis, antioxidant and in vivo anti-inflammatory activity and LOX inhibition of a wide number of new 
quinoxaline and quinoxaline 1,4-di-N-oxide derivatives. Several structural modifications have been carried out 
(Figure 1) in order to determine the structural requirements of this kind of compounds to act as anti-inflammatory and 
antioxidant agents. 
Results and Discussion 
Synthesis 
The new compounds of series 1, 2 and 3 were synthesized following the previous described procedures.18 The 
starting reagents, 5-substituted or 5,6-disubstituted benzofuroxanes (BFX) I were obtained by previously reported 
methods.19 
 
                                                 
a,*Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece. 
Email: hadjipav@pharm.auth.gr. Fax: +302310997679. Tel: +302310997627. 
bUnidad de Investigación y Desarrollo de Medicamentos, Centro de Investigación en Farmacobiología Aplicada (CIFA), University 
of Navarra, c/Irunlarrea s/n, 31080 Pamplona, Spain 
 
N
+
N
+
OO
O
R7 O
O
O
N
+
N
+
OO
O
R7 O
OH
N
+
N
+
O
O
R7
N
H
N
O
O
O
N
+
N
+
OO
O
R7 O
O
O
R6
N
+
N
+
OO
O
R7 O
OHR6
N
+
N
+
O
O
R7
N
H
N
O
R4'
R6 R3'
N
N
O
R7 O
O
O
R6 N
NR7
N
H
N
O
O
OR6
N
NR7
NN
O
O
OR6
S NH2
O
O
N
+
N
+
O
O
R7
O
O
R6
N
+
N
+
O
O
R7 O
O
O
O
R6
N
NR7
R6
NN
O
O
O
NH2
PREVIOUS LEADS
Series 1 (1a) Series 3 (3a, 3b)
Series 2
Series 2
Series 1
Series 4
Series 5
Series 6
Series 7
Series 3 (R3'=R4'=OCH3)
Series 8
Series 9
1b, 1e, 1f
6a, 6b, 6c, 6d, 6e, 6f
4a, 4b, 4c, 4d, 4e, 4f
5a, 5b, 5d, 5e, 5g
7a, 7b, 7c, 7d, 7e
2e, 2f
3c, 3e, 3f
8c, 8f
9a, 9b, 9c, 9d
10a
(2a, 2b, 2c)
R6/R7: H/H (a); H/F(b); H/OCH3 (c); H/Cl (d); H/CH3 (e); CH3/CH3 (f); F/F (g)
Series 10 (R3'=H; R4'=OH)
Fig 1. Chemical structure modifications of the previous lead compounds 
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Scheme 1. Reagents and conditions: (a) 4,4-dimethoxy-butan-2-one (series 4) or 3,3-dimethoxy-propionaldehyde 
(series 5), pyrrolidine; (b) Butan-2-one (series 4) or Propionaldehyde (series 5), morpholine (c) HCl/MeOH, DCM 
extraction; (d) SeO2/acetonitrile, 5', 200 W (MW); (e) Br2/CH3COOH; (f) Toluene, NaH/H2O; (g) Xylene, 1'30'', 110 
W (MW), NaH/H2O; (h) DCM reflux, 5/6 hours; (i) MeOH, 5', 25 W (MW) 
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Scheme 2. Reagents and conditions:(a) Pentane-2,4-dione, triethylamine (b) Na2S2O4, methanol, 70ºC; (c) 3,4,5-
Trimethoxy-benzaldehyde, 3% NaOH/methanol, r.t; (d) guanidine hydrochloride, 10% KOH/isopropanol reflux, 24h; 
(e) NH2NH2, ethanol, r.t.; (f) 4-hydrazinobenzene-1-sulfonamide hydrochloride 97%, ethanol, 20', 50 W (MW) 
The classic Claisen-Schmidt condensation, used to synthesize compounds with α,β-unsaturated ketone system 
(such as compounds in series 1), did not react in the same expected way to obtain compounds in series 4 and 5. Thus, 
a Wittig reaction was proposed to obtain the desired compounds (Scheme 1). Usually, these reactions, that consist in 
a condensation between an aldehyde and an ylide to afford the corresponding α,β-unsaturated ketone system 
derivative, are carried out in a dichloromethane reflux during 5 or 6 hours.20 After a deep study of the reaction 
conditions we optimized a microwave assisted method for the synthesis of these two series concluding that the use of 
the microwave improved conversion ratios and decreased reaction times. As shown in Scheme 1, both aldehyde and 
ylide had to be previously synthesized. Aldehydes IV were obtained by two different methods: one of them included 
deprotection of an acetal group in acid medium; the other involved a methyl oxidation using SeO2 as the oxidant 
agent.21 The second method was found to be the most appropriate for the synthesis of these aldehydes as a huge 
volume of solvent was needed in the first one to do the extraction. In addition, a microwave assisted method was 
developed by our group to carry out this reaction. The starting compounds II and III were synthesized by the classic 
Beirut reaction22 between the appropriate BFX and the corresponding carbonilic derivative using pyrrolidine or 
morpholine as the catalyst. Obtention of ylide VI required a reaction between triphenylphosphine and the 
corresponding alkyl halide V and a subsequent treatment with a weak base.20 In the case of series 5, the halide was 
commercially available and the formation of the ylide was carried out by using a microwave assisted method. The 
synthesis of ylide in series 4 was performed by a conventional route as the microwave did not work as expected with 
this reaction. The required halide was previously synthesized as reported20 and used without purification to obtain the 
ylide, that could be the reason of the failure of the microwave assisted synthesis. 
Synthesis of series 6 was carried out by a Claisen-Schmidt condensation between the corresponding 6,7-
substituted 2-acetyl-3-methyl quinoxaline VIII and 3,4,5-Trimethoxy-benzaldehyde using 3% sodium hydroxide in 
methanol (Scheme 2). Starting compounds VIII were obtained by reduction of the N-oxide groups23 of compounds 
VII24 with Na2S2O4. While the reaction to obtain series 1 was performed at low temperature18 it was possible to carry 
out the condensation at room temperature to obtain compounds of series 6 and this fact resulted in much better yields. 
Cyclization of the α,β-unsaturated ketone system in compounds of series 6 yield compounds of series 7, 8 and 9 
(Scheme 2). Formation of a six-membered ring (series 7) was carried out in an isopropanol reflux in the presence of 
guanidine and KOH as the catalyst. Reaction between compounds of series 6 and hydrazine gave compounds of 
series 8 and in the same way, compounds of series 2 reacted with hydrazine to afford compounds of series 10. The 
conventional method to synthesize 3,5-substituted 1-(4-sulfamylphenyl) pyrazolines (compounds 9) consists of an 
eight-hour ethanol reflux.25 We optimized a microwave assisted method for the preparation of this series 9 and we 
managed to reduce the volume of solvent, the reaction times and, as a consequence, possible secondary reactions. 
Antioxidant activity 
The estimation of the antioxidant potential of the synthesized compounds was assessed by several different assays 
in order to study a wider spectrum of scavenging properties. The results obtained were compared to well known  
 
Table 1. Interaction percentage with DPPH (DPPH %) at 0.05 mM, 0.1 mM and 0.2 mM; Antioxidant 
determination using the ABTS cation radical-percentage inhibition (ABTS %) 
 DPPH % ABTS % 
Compound 0.05 mM 0.1 mM 0.2 mM 0.1 mM 
 20 min 60 min 20 min 60 min 20 min 60 min  
1b No No 1.4 2.3 0.4 1.7 19.2 
1e 6.5 0.8 2.5 4.3 No No 2.1 
1f 2.4 No No No No No 8.8 
2e 11.4 12.0 28.7 37.7 39.7 50.1 92.3 
2f 15.9 18.8 32.2 41.4 50.8 62.9 84.3 
3c 58.5 65.9 58.5 70.1 65.5 78.7 48.3 
3e 44.1 54.9 40.6 55.5 55.7 66.8 40.2 
3f 24.9 41.3 53.3 62.5 89.6 94.0 50.5 
4a No No 7.5 11.9 2.8 No No 
4b 7.4 6.9 No 3.3 No No No 
4c 3.2 3.9 3.9 6.0 No No 11.1 
4d 0.7 No 2.4 No No No No 
4e No No 0.6 2.9 1.0 3.6 9.1 
4f 0.3 No 2.9 1.6 No 2.4 No 
5a 0.6 1.1 0.8 3.0 4.4 No 12.1 
5b 3.7 4.5 2.1 No No 1.1 No 
5d 3.3 1.8 No 2.5 No No 10.0 
5e No No No 4.0 No 0.1 No 
5g No No No No No No 6.5 
6a 6.0 4.0 1.0 1.0 No No 39.3 
6b 2.0 4.0 2.0 2.0 1.0 2.0 81.0 
6c 7.0 3.0 3.0 No 2.0 4.0 80.6 
6d 5.0 6.0 7.0 2.0 3.0 5.0 79.7 
6e 8.0 3.0 No No 5.0 3.0 72.0 
6f 3.0 3.0 6.0 1.0 5.0 5.0 55.2 
7a 1.7 7.3 4.3 0.3 5.5 3.9 18.1 
7b 6.3 8.9 10.7 14.6 13.0 18.8 40.6 
7c No No No 0.6 No No No 
7d 0.6 1.7 No No No 0.9 No 
7e 0.4 2.9 No 1.3 No 2.2 4.3 
8c 11.7 22.5 19.2 37.3 26.4 45.0 74.2 
8f 13.4 23.5 24.6 42.9 35.8 52.5 76.1 
9a 5.1 4.4 6.7 8.0 10.8 6.4 2.6 
9b No No No No No No No 
9c No No No No No No 10.1 
9d No No No No No 1.0 5.8 
10a 49.2 60.6 62.7 72.4 83.3 87.7 71.6 
NDGA 68 72 81 83    
Trolox       88 
No: no result under the experimental conditions; each experiment was performed at least in triplicate and the 
standard deviation of absorbance was less than 10% of the mean; NDGA nordihydroguaiaretic acid 
antioxidants agents such as nordihydroguaeretic acid (NDGA), trolox, and caffeic acid. Most of the experimental 
procedures required a spectrophotometric measurement and a certain reaction time to obtain reproducible results. 
DPPH interaction. One such method that is currently popular is based upon the use of 1,1-diphenyl-2-picrylhydrazyl 
(DPPH). DPPH is a stable free radical with a spare electron, which is delocalized over the whole molecule. The 
delocalization causes deep violet color with λmax around 517nm. When an ethanolic solution of DPPH is mixed with 
that of a compound that can donate a hydrogen atom, then this gives rise to the reduced form with the loss of the 
characteristic color. This interaction indicates radical scavenging ability in an iron-free system. Our compounds were 
examined for their DPPH interaction at 0.05 mM, 0.1 mM and 0.2 mM after 20 and 60 min (table 1). 
Compounds of series 2, 3, 8 and 10 (2e, 2f, 3c, 3e, 3f, 8c, 8f and 10a), showed the best DPPH interaction 
percentage values, some of them displaying similar values (70-72%) to that of the reference compound NDGA (83%) 
at the same concentration. These compounds have either a phenolic group or a free amino pyrazoline ring in their 
structure, so they are able to donate a hydrogen atom. The most interesting derivatives were those with the pyrazoline 
moiety (compounds 3c, 3e, 3f, 8c, 8f and 10a) and among them, those with N-oxide groups in the quinoxaline ring 
(3c, 3e, 3f and 10a) exhibited significantly increased activity compared to their reduced analogues (8c and 8f). Thus, 
the presence of the N-oxide groups in these compounds might increase the acidity of the amino group making easier 
the release of the hydrogen atom and so increasing their scavenging activity. The presence of both NH and OH 
groups in the same molecule (compound 10a) seemed to strengthen its antioxidant character. 
For compounds 2e, 2f, 3c, 3e, 3f the interaction values were found to be time and concentration dependent. 
Table 2. Superoxide radical scavenging activity (PMS %); Competition percentage with DMSO for hydroxyl 
radical (OH %); Inhibition of linoleic acid lipid peroxidation induced by AAPH (AAPH) 
PMS % OH % AAPH
Compound 
0.01 mM 0.1 mM 0.1 mM AAPH % 0.1 mM IC50 (mM) 
1b 20.0 75.0 99.7  0.091 
1e - No 92.5  0.100 
1f - No 91.5 35.3 - 
2e No 62.5 No 24.3 - 
2f - 6.3 95.9 28.2 - 
3c - No 94.4  0.084 
3e - No 96.0 29.0 - 
3f - No 99.6 43.8 - 
4a - No 94.5 No - 
4b - 25.0 96.3 No - 
4c - No 97.8 No - 
4d - No 87.6 3.6 - 
4e - No 94.6 13.0 - 
4f - 57.1 98.5 18.2 - 
5a - 50.0 98.4 11.2 - 
5b 50.0 96.4 96.6 6.8 - 
5d - No 95.2 10.1 - 
5e - No 97.6 22.6 - 
5g - 50.0 96.9 9.0 - 
6a 81.1 79.0 91.0 50.5 - 
6b 51.4 100 87.0  0.010 
6c 52.8 100 84.0 45.0 - 
6d 52.8 100 85.0 21.5 - 
6e 97.2 100 85.0  <0.010 
6f 81.1 78.9 92.0 45.4 - 
7a - No No  0.053 
7b - 50.0 No  0.073 
7c - No 77.7  0.094 
7d - 31.3 91.8  0.078 
7e - No No  0.089 
8c - No No 2.9 - 
8f - No 82.6  0.078 
9a - No 92.9  0.023 
9b - No 97.4  0.072 
9c - No 92.6 8.5 - 
9d - No 87.0  0.077 
10a 50.0 68.8 98.3  0.074 
Caffeic acid 45     
Ascorbic acid    95.8  
Trolox   88.2 63.0  
No: no result under the experimental conditions; - not tested; each experiment was performed at least in triplicate 
and the standard deviation of absorbance was less than 10% of the mean 
ABTS assay. Another existing method to evaluate antioxidant activity is the ABTS radical cation decolorization 
assay.26 The pre-formed radical monocation of 2,2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS·+) is 
generated by oxidation of ABTS with potassium persulfate and reduced in the presence of hydrogen-donating 
antioxidants. The decolorization of the blue/green solution (due to the ABTS·+ color) after the treatment with the 
compound is indicative of its scavenging ability. 
In the same way as DPPH interaction, the best activities in the ABTS assay (table 1) were shown by compounds of 
series 2, 3, 8 and 10 (2e, 2f, 3c, 3e, 3f, 8c, 8f and 10a) with a phenolic group and/or a free amino pyrazoline ring in 
the structure. Nevertheless, these activities seemed to have the opposite trend of that showed in the DPPH assay, as 
the best derivatives were those with a phenol group (compounds 2e and 2f) followed by compounds of series 8 (8c 
and 8f) and series 3 (3c, 3e and 3f). Surprisingly, compounds of series 6 (6a-f)showed quite good values of ABTS·+ 
scavenging ability as well as compound 7b that displayed an activity similar to that of compounds of series 3. 
Superoxide radical anion (·O2-) and hydroxyl radical (·OH) scavenging activity. The ability of the compounds to 
scavenge superoxide radical anion and hydroxyl radical was also evaluated. Superoxide anion is considered to be the 
“primary” ROS that initiates the generation of other ROS such as hydrogen peroxide and hydroxyl radicals.27 These 
toxic oxygen species are involved in the oxidative damage to DNA, proteins and other macromolecules leading to the 
development of several degenerative diseases associated with aging.28 
Generation of non enzymatic superoxide anion radicals was carried out by mixing phenazine methosulfate (PMS), 
nicotinamide adenine dinucleotide NADH and air-oxygen. The production of superoxide was estimated by the 
nitroblue tetrazolium method.29 As shown in the table 2 compounds with an α,β-unsaturated ketone system (1b, 2e, 
4f, 5a, 5b, 5g and 6a-f) presented the best superoxide scavenging activities (higher than that of Caffeic acid used as 
the reference compound) being the reduced derivatives (6a-f) the most interesting structures with interaction values 
between 79 and 100 %. This evidence led us to affirm that the olefinic moiety might play an important role in the 
activity of these compounds by trapping the superoxide radical. The presence of the N-oxide groups in the molecules 
greatly decreases their scavenging ability. 
The competition of compounds with dimethyl sulfoxide (DMSO) for ·OH radicals, generated by the Fe3+/ascorbic 
acid system, expressed as the inhibition of formaldehyde production, was used for the evaluation of their hydroxyl 
radical scavenging activity. Most of the tested compounds exhibited high competition percentage values at 0.1mM 
(Table 2), similar to that of Trolox used as the reference compound, which indicates that these derivatives are good 
hydroxyl radical scavengers. 
Inhibition of linoleic acid lipid peroxidation. Lipid peroxidation in cell membrane has been proposed to be a major 
mechanism for several pathological events including cancer, Parkinson’s disease and aging.30The ability of the 
compounds to inhibit lipid peroxidation was measured.31 Production of conjugated diene hydroperoxide by oxidation 
of linoleic acid in an aqueous dispersion was monitored at 234 nm. 2,2’-Azobis(2-amidinopropane) dihydrochloride 
(AAPH) was used as a free radical initiator. 
The results (Table 2) showed that compounds 6b and 6e were the best inhibitors of lipid peroxidation displaying 
IC50 values of 0.01 mM and <0.01 mM respectively. Compounds of series 7 (7a, 7b, 7d and 7e) and 9 (9b and 9d), 
having a free amino group in their structure, also presented good inhibition activities, especially those with a 
hydrogen atom (7a and 9a) in position R7 of the quinoxaline ring. Replacement of the hydrogen by a fluoro atom (7b 
and 9b) resulted in a decrease in the activity, although fluoro derivatives showed also interesting inhibition values of 
lipid peroxidation. 
Inhibition of Soybean lipoxygenase (LOX) 
The assay for lipoxygenase (LOX) activity was carried out according to the UV absorbance based enzyme assay32, 
33 using soybean lipoxygenase. While one may not extrapolate the quantitative results of this assay to the inhibition of 
mammalian 5-LOX, it has been shown that inhibition of plant LOX activity by NSAIDs is qualitatively similar to 
their inhibition of the rat mast cell LOX and may be used as a simple qualitative screen for such activity. 
In general, compounds that displayed good activities as inhibitors of lipid peroxidation also presented good values 
of inhibition of LOX (table 3). Thus, the best IC50 values were shown by compounds of series 7 and 9 
(7b>7e>9b>8f>9d>7a). From series 8 only compound 8f presented significant activity. Nevertheless, while the best 
inhibitors of lipid peroxidation were those compounds without any substitution in the quinoxaline ring, the most 
interesting activities of LOX inhibition were obtained by fluoro and methyl substituted derivatives. 
In vivo anti-inflammatory activity 
Two compounds, 7b (which was the most potent LOX inhibitor) and 8f (the most potent from series 8), were 
tested as in vivo anti-inflammatory agents. In acute toxicity experiments, the in vivo examined compounds 7b and 8f 
did not present toxic effects in doses up to 0.2 mmol/kg body weight. Ulcerogenicity was not found. Acute 
inflammation is due to the release of chemical mediators, which cause edema as a result of extravasations of fluid and 
proteins from the local microvasculature and accumulation of polymorphonuclear leukocytes at the inflammatory 
site. The in vivo anti-inflammarory effects of the tested quinoxaline derivatives were assessed by using the 
carrageenin-induced rat paw edema (CPE) model and are presented in Table 3 as percentage of weight increase at the 
right hind paw. The induced edema is a non-specific inflammation highly sensitive to non-steroidal anti-inflammatory 
agents (NSAIDs). Thus it has been accepted as a useful tool for studying new anti-inflammatory agents.34 It reliably 
predicts the anti-inflammatory potency of the NSAIDs and detects during the second phase that are anti-inflammatory 
agents as a result of inhibition of prostaglandin amplification.35 Compound 7b showed 41.3 % percentage of  
Table 3. Inhibition percentage of induced carrageenin rat paw edema (CPE %) at 0.01 mmol/kg; In vitro inhibition 
of soybean lipoxygenase (LOX) inhitibion % at 0.1 mM / IC50 (mM) 
LOX  
Compound CPE %a
inhibition % at 
0.1 mM IC50 (mM) Clog PP
b
1b   0.090 -0.01 
1e  35.4 - 0.20 
1f  36.7 - 0.64 
2e  12.2 - 0.08 
2f  26.0 - 0.53 
3c  38.4 - -0.33 
3e   0.095 -0.09 
3f   0.100 0.35 
4a  30.0 - 0.17 
4b  No - 0.46 
4c  26.6 - 0.43 
4d  40.3 - 1.03 
4e  40.4 - 0.67 
4f  18.7 - 1.12 
5a  4.0 - 0.29 
5b  19.7 - 0.58 
5d  2.4 - 1.15 
5e  5.0 - 0.79 
5g  23 - 0.71 
6a   0.140 2.49 
6b   0.200 2.60 
6c   0.320 2.82 
6d   0.350 3.17 
6e   0.088 3.37 
6f   0.410 2.93 
7a   0.050 3.00 
7b 41.3*  0.023 3.14 
7c  21.6 - 3.19 
7d   0.089 3.71 
7e   0.036 3.50 
8c  37.9 - 2.53 
8f 28.2 *  0.042 3.08 
9a  3.0 - 3.90 
9b   0.037 4.07 
9c  No - 4.29 
9d   0.043 4.64 
10a   0.092 -0.71 
Caffeic acid   0.600  
IMA 47*    
No: no result under the experimental conditions; - not tested; each experiment was performed at least in triplicate 
and the standard deviation of absorbance was less than 10% of the mean; IMA indomethacin; a statistical studies 
were done with student’s T-test, *p<0.01; b Reference 37 in the text. 
protection while the reference drug indomethacin induced 47 % protection at an equivalent dose. Compound 8f 
was less potent (28.2 %). No role for lipophilicity was found. Both derivatives presented similar Clog P values (Table 
3). 
Experimental Section 
Chemistry 
Microwave assisted synthesis was carried out in a Discover S-Class microwave system apparatus (CEM 
Corporation). The 1H NMR spectra were recorded on a Bruker 400 UltrashieldTM (Bruker BioSpin GmbH, 
Rheinstetten, Germany), using TMS as the internal standard and with CDCl3 and DMSO-d6 as the solvents; the 
chemical shifts are reported in ppm (δ) and the coupling constant (J) values are given in Hertz (Hz). Signal 
multiplicities are represented by: s (singlet), bs (broad singlet), d (doublet), dd (double doublet), t (triplet), and m 
(multiplet) The IR spectra were performed on Thermo Nicolet FT-IR Nexus Euro (Madison, USA) using KBr pellets; 
the frequencies are expressed in cm-1. Elemental microanalyses were obtained on an Elemental Analyzer LECO 
CHN-900 (Michigan, USA) from vacuum-dried samples. The analytical results for C, H, and N were within ± 0.4 of 
the theoretical values, indicating a purity of >95%. 
Alugram® SIL G/UV254 (Layer: 0.2 mm) (Macherey-Nagel GmbH & Co. KG. Postfach 101352. D-52313 Düren, 
Germany) was used for Thin Layer Chromatography and Silica gel 60 (0.040-0.063 mm) for Column Flash 
Chromatography (Merck). 
All reagents and solvents were purchased from commercial sources. E. Merck (Darmstadt, Germany), Scharlau 
(F.E.R.O.S.A., Barcelona, Spain), Panreac Química S.A. (Montcada i Reixac, Barcelona, Spain), Sigma-Aldrich 
Química, S.A., (Alcobendas, Madrid), Acros Organics (Janssen Pharmaceuticalaan 3a, 2440 Geel, België) and 
Lancaster (Bischheim-Strasbourg, France). 
General method for the microwave assisted synthesis of 1,4-dioxy-quinoxaline-2-carbaldehyde derivatives 
(compounds IV). In a microwave reaction flask 3 mmol of the appropriate compound III, 4.5 mmol of SeO2 and 20 
mL of acetonitrile were mixed. The reaction was carried out at 200 W for 5 minutes. The solvent was evaporated, an 
extraction with chloroform and water was performed and the residue purified by column chromatography using 
toluene:dioxane (3:2). The compounds obtained have been previously described.20,36 
General method for the microwave assisted synthesis of 1-(substituted-phenyl)-2-(triphenyl-phosphonylidene)-
ethanone derivatives (compounds VI). 5 mmol of triphenylphosphine, 5 mmol of the corresponding halide V and 3 
mL of xylene were mixed in a microwave reaction flask. The program was run for 1 minute and 30 seconds at 110 W. 
The residue was dissolved in 10 mL of methanol and 8 mmol of NaH in water were added. The mixture was extracted 
with ethyl ether (3 x 25 mL), the organic phase dried with anhydrous Na2SO4 and the solvent removed under vacuum 
to yield compounds VI. Spectroscopic data for compounds VI are listed below. 
1-(3,4,5-trimethoxy-phenyl)-2-(triphenyl-phosphonylidene)-ethanone (VI-a). The compound VI-a was obtained 
as a white solid (42%). IR (KBr) 1664 (C=O), 1584-1463 (C-C ar), 1122 (C-O-C); 1NMR (CDCl3) δ: 3.88 (s, 3H, p-
OCH3), 3.92 (s, 6H, m-OCH3), 4.35-4.40 (d, 1H, =CH, JH-P=19.05 Hz), 7.26 (s, 2H, H2+H6), 7.48-7.53 (m, 6H, 
H3’+H5’), 7.57-7.61 (m, 3H, H4’), 7.71-7.76 (m, 6H, H2’+H6’); Analysis calculated for C29H27O4P (470.51): C, 74.04; 
H, 5.74; N, 0.00. Found: C, 73.82; H, 5.70; N, 0.00. 
1-(4-methoxy-phenyl)-2-(triphenyl-phosphonylidene)-ethanone (VI-b). The compound VI-b was obtained as a 
white solid (37%). IR (KBr) 1649 (C=O), 1598-1482 (C-C ar), 1184 (C-O-C); 1NMR (DMSO-d6) δ: 3.77 (s, 3H, 
OCH3), 4.37-4.44 (d, 1H, =CH, JH-P=24.95 Hz), 6.88-6.90 (d, 2H, H3+H5, J32/56=8.76 Hz), 7.54-7.59 (m, 6H, 
H3’+H5’), 7.64-7.70 (m, 6H, H2’+H4’+H6’), 7.81-7.83 (d, 2H, H2+H6, J23/65=8.74 Hz); Analysis calculated for 
C27H23O2P (410.46): C, 79.01; H, 5.65; N, 0.00. Found: C, 78.65; H, 5.60; N, 0.00. 
Synthesis of 1-(3-Methyl-quinoxalin-2-yl)-ethanone derivatives (Compounds VIII). These compounds were 
obtained following the procedure described in the literature.23 Spectroscopic data for one of these derivatives (VIIIa, 
R6/R7=H/H) is described below as a reference compound. 
1-(3-Methyl-quinoxalin-2-yl)-ethanone (VIIIa). A 218 mg portion of 2-Acetyl-3-methylquinoxaline 1,4-di-N-oxide 
(1 mmol) was dissolved in 20 mL of methanol. The solution was heated at 70ºC and 1.04 g of Na2S2O4 (6 mmol) in 
10 mL of water were added. The mixture was stirred for 10 minutes and the solvent removed under reduced pressure. 
The solid obtained (50 % yield) was filtered and washed with water. IR (KBr) 1694 (C=O); 1H-NMR (DMSO-d6) δ: 
2.76 (s, 3H, 3-CH3), 2.84 (s, 3H, CO-CH3), 7.86-7.90 (ddd, 1H, H6, J65=8.31 Hz, J67=6.93 Hz, J68=1.49 Hz), 7.93-
7.97 (ddd, 1H, H7, J78=8.38 Hz, J76=6.92 Hz, J75=1.52 Hz), 8.05-8.07 (dd, 1H, H5, J56=8.34 Hz, J57=1.09 Hz), 8.14-
8.16 (dd, 1H, H8, J87=8.28 Hz, J86=1.08 Hz); Analysis calculated for C11H10N2O (186.22): C, 70.95; H, 5.41; N, 
15.04. Found: C, 70.63; H, 5.33; N, 15.08. 
General method for the microwave assisted synthesis of 3-(3-Methyl-1,4-dioxy-quinoxalin-2-yl)-1-(3,4,5-
trimethoxy-phenyl)-propenone derivatives (Series 4) and of 3-(1,4-dioxy-quinoxalin-2-yl)-1-(4-methoxy-
phenyl)-propenone derivatives (Series 5). In a microwave reaction flask 0.25 mmol of aldehyde IV, 0.375 mmol of 
the corresponding ylide VI and 1 mL of methanol were mixed. The reaction was carried out at 25 W for 5 minutes. 
The solid obtained was filtered and purified by flash column chromatography using toluene:dioxane (3:2) as the 
eluent. 
(2E)-3-(3-Methyl-1,4-dioxy-quinoxalin-2-yl)-1-(3,4,5-trimethoxy-phenyl)-propenone (4a). The derivative 4a was 
obtained as yellow solid (27%). IR (KBr) 1651 (C=O), 1317 (N-O), 1120 (C-O-C); 1H-NMR (CDCl3) δ: 2.95 (s, 3H, 
CH3), 3.98 (s, 3H, p-OCH3), 4.00 (s, 6H, m-OCH3), 7.40 (s, 2H, H2’+H6’), 7.93-7.81 (m, 3H, H6+H7+Hb), 8.73-8.62 
(m, 2H, H5+H8), 9.20 (d, 1H, Ha, Jab=15.26 Hz); Analysis calculated for C21H20N2O6 (396.40): C, 63.60; H, 5.09; N, 
7.07. Found: C, 63.73; H, 4.99; N, 6.90. 
(2E)-3-(7-Fluoro-3-methyl-1,4-dioxy-quinoxalin-2-yl)-1-(3,4,5-trimethoxy-phenyl)-propenone (4b). The 
compound 4b was obtained as yellow solid (24%). IR (KBr) 1650 (C=O), 1319 (N-O), 1120 (C-O-C); 1H-NMR 
(CDCl3) δ: 2.93 (s, 3H, CH3), 3.99 (s, 3H, p-OCH3), 4.00 (s, 6H, m-OCH3), 7.40 (s, 2H, H2’+H6’), 7.61-7.65 (ddd, 
1H, H6, J65=9.61 Hz, J6F=7.35 Hz, J68=2.46 Hz), 7.82-7.86 (d, 1H, Hb, Jba=15.24 Hz), 8.31-8.34 (dd, 1H, H8, J8F= 
8.67 Hz, J86=2.59 Hz), 8.70-8.74 (dd, 1H, H5, J56=9.48 Hz, J5F=5.09 Hz), 9.20-9.23 (d, 1H, Ha, Jab=15.25 Hz); 
Analysis calculated for C21H19FN2O6 (414.38): C, 60.87; H, 4.62; N, 6.76. Found: C, 60.62; H, 4.76; N, 6.51. 
(2E)-3-(7-Methoxy-3-methyl-1,4-dioxy-quinoxalin-2-yl)-1-(3,4,5-trimethoxy-phenyl)-propenone (4c). The 
derivative 4c was obtained as yellow solid (37%). IR (KBr) 1657 (C=O), 1320 (N-O), 1133 (C-O-C); 1H-NMR 
(CDCl3) δ: 2.90 (s, 3H, CH3), 3.97 (s, 3H, p-OCH3), 3.99 (s, 6H, m-OCH3), 4.05 (s, 3H, quinox-OCH3), 7.39 (s, 2H, 
H2’+H6’), 7.44-7.47 (dd, 1H, H6, J65=9.43 Hz, J68=2.61 Hz), 7.84-7.87 (d, 1H, Hb, Jba=15.23 Hz), 7.94 (d, 1H, H8, 
J86=2.68 Hz), 8.55-8.58 (d, 1H, H5, J56=9.45 Hz), 9.13-9.17 (d, 1H, Ha, Jab=15.28 Hz); Analysis calculated for 
C22H22N2O7 (426.43): C, 61.97; H, 5.20; N, 6.57. Found: C, 61.63; H, 5.66; N, 6.14. 
(2E)-3-(7-Chloro-3-methyl-1,4-dioxy-quinoxalin-2-yl)-1-(3-hydroxy-4,5-dimethoxy-phenyl)-propenone (4d). 
The derivative 4d was obtained as orange solid (30%). IR (KBr) 1654 (C=O), 1321 (N-O), 1135 (C-O-C); 1H-NMR 
(CDCl3) δ: 2.93 (s, 3H, CH3), 3.99 (s, 3H, p-OCH3), 4.00 (s, 6H, m-OCH3), 7.39 (s, 2H, H2’+H6’), 7.81-7.84 (dd, 1H, 
H6, J65=9.11 Hz, J68=2.18 Hz), 7.81-7.85 (d, 1H, Hb, Jba=15.20 Hz), 8.63-8.65 (d, 1H, H5, J56=9.13 Hz), 8.66-8.67 (d, 
1H, H8, J86=2.15 Hz), 8.19-8.23 (d, 1H, Ha, Jab=15.25 Hz); Analysis calculated for C21H19ClN2O6 (430.89): C, 58.54; 
H, 4.45; N, 6.50. Found: C, 58.58; H, 4.41; N, 6.32. 
(2E)-3-(3,7-Dimethyl-1,4-dioxy-quinoxalin-2-yl)-1-(3,4,5-trimethoxy-phenyl)-propenone (4e). The compound 4e 
was obtained as yellow solid (33%). IR (KBr) 1654 (C=O), 1322 (N-O), 1126 (C-O-C); 1H-NMR (CDCl3) δ: 2.66 (s, 
3H, 7-CH3), 2.94 (s, 3H, 3-CH3), 3.99 (s, 3H, p-OCH3), 4.00 (s, 6H, m-OCH3), 7.41 (s, 2H, H2’+H6’), 7.71-7.73 (dd, 
1H, H6, J65=8.74 Hz, J68=1.62 Hz), 7.84-7.88 (d, 1H, Hb, Jba=15.27 Hz), 8.45 (s, 1H, H8), 8.56-8.59 (d, 1H, H5, 
J56=8.75 Hz), 9.14-9.18 (d, 1H, Hb, Jba=15.29 Hz); Analysis calculated for C22H22N2O6 (410.42): C, 64.39; H, 5.37; 
N, 6.83. Found: C, 64.19; H, 5.40; N, 6.64. 
(2E)-1-(3-Hydroxy-4,5-dimethoxy-phenyl)-3-(3,6,7-trimethyl-1,4-dioxy-quinoxalin-2-yl)-propenone (4f). The 
compound 4f was obtained as yellow solid (36%). IR (KBr) 1654 (C=O), 1321 (N-O), 1128 (C-O-C); 1H-NMR 
(CDCl3) δ: 2.55 (s, 6H, 6,7-CH3), 2.93 (s, 3H, 3-CH3), 3.98 (s, 3H, p-OCH3), 3.99 (s, 6H, m-OCH3), 7.40 (s, 2H, 
H2’+H6’), 7.83-7.87 (d, 1H, Hb, Jba=15.27 Hz), 8.39 (s, 1H, H5), 8.42 (s, 1H, H8) 9.13-9.17 (d, 1H, Ha, Jab=15.28 Hz); 
Analysis calculated for C23H24N2O6 (424.45): C, 65.08; H, 5.70; N, 6.60. Found: C, 65.16; H, 5.57; N, 6.46. 
(2E)- 3-(1,4-Dioxy-quinoxalin-2-yl)-1-(4-methoxy-phenyl)-propenone (5a). The derivative 5a was obtained as 
yellow solid (46%). IR (KBr) 1663 (C=O), 1374 (N-O), 1174 (C-O-C); 1H-NMR (DMSO-d6) δ: 3.90 (s, 3H, OCH3), 
7.12-7.15 (d, 2H, H2’+H6’, J2’3’/J6’5’=8.78 Hz), 7.98-8.01 (m, 2H, H6+H7), 8.05-8.09 (d, 1H, Hb, Jba=15.93 Hz), 8.22-
8.24 (d, 2H, H3’+H5’, J3’2’/J5’6’=8.70 Hz), 8.47-8.54 (m, 2H, H5+H8), 8.58-8.62 (d, 1H, Ha, Jab=15.95 Hz), 9.53 (s, 
1H, H3); Analysis calculated for C18H14N2O4 (322.32): C, 67.08; H, 4.35; N, 8.70. Found: C, 67.14; H, 4.43; N, 8.71. 
(2E)-3-(7-Fluoro-1,4-dioxy-quinoxalin-2-yl)-1-(4-methoxy-phenyl)-propenone (5b). The compound 5b was 
obtained as yellow solid (32%). IR (KBr) 1661 (C=O), 1372 (N-O), 1177 (C-O-C); 1H-NMR (DMSO-d6) δ: 3.89 (s, 
3H, OCH3), 7.13-7.15 (d, 2H, H2’+H6’, J2’3’/J6’5’=8.83 Hz), 7.90-7.95 (m, 1H, H6), 8.02-8.06 (d, 1H, Hb, Jba=15.96 
Hz), 8.22-8.24 (m, 3H, H8+H3’+H5’), 8.58-8.62 (m, 2H, Ha+H5), 9.59 (s, 1H, H3); Analysis calculated for 
C18H13FN2O4 (340.31): C, 63.53; H, 3.82; N, 8.24. Found: C, 63.29; H, 3.72; N, 8.02. 
(2E)-3-(7-Chloro-1,4-dioxy-quinoxalin-2-yl)-1-(4-methoxy-phenyl)-propenone (5d). The derivative 5d was 
obtained as yellow solid (71%). IR (KBr) 1661 (C=O), 1374 (N-O), 1177 (C-O-C); 1H-NMR (DMSO-d6) δ: 3.89 (s, 
3H, OCH3), 7.13-7.15 (d, 2H, H2’+H6’, J2’3’/J6’5’=8.78 Hz), 8.02-8.06 (m, 2H, H6+Hb), 8.21-8.23 (d, 2H, H3’+H5’, 
J3’2’/J5’6’=8.27 Hz), 8.47-8.63 (m, 3H, Ha+H5+H8), 9.58 (s, 1H, H3); Analysis calculated for C18H13ClN2O4 (356.77): 
C, 60.59; H, 3.65; N, 7.85. Found: C, 60.23; H, 3.52; N, 7.64. 
(2E)-1-(4-Methoxy-phenyl)-3-(7-methyl-1,4-dioxy-quinoxalin-2-yl)-propenone (5e). The compound 5e was 
obtained as yellow solid (39%). IR (KBr) 1657 (C=O), 1373 (N-O), 1171 (C-O-C); 1H-NMR (DMSO-d6) δ: 2.60 (s, 
3H, CH3), 3.90 (s, 3H, OCH3), 7.13-7.15 (d, 2H, H2’+H6’, J2’3’/J6’5’=8.91 Hz), 7.82-7.84 (dd, 1H, H6, J65=8.81 Hz, 
J68=1.74 Hz), 8.04-8.08 (d, 1H, Hb, Jba=15.96 Hz), 8.22-8.24 (d, 2H, H3’+H5’, J3’2’/J5’6’=8.94 Hz), 8.30 (s, 1H, H8), 
8.41-8.43 (d, 1H, H5, J56=8.76 Hz), 8.56-8.60 (d, 1H, Ha, Jab=15.97 Hz), 9.50 (s, 1H, H3); Analysis calculated for 
C19H16N2O4 (336.35): C, 67.86; H, 4.76; N, 8.33. Found: C, 67.68; H, 4.51; N, 8.55. 
(2E)-3-(6,7-Difluoro-1,4-dioxy-quinoxalin-2-yl)-1-(4-methoxy-phenyl)-propenone (5g). The compound 5g was 
obtained as yellow solid (14%). IR (KBr) 1662 (C=O), 1374 (N-O), 1176 (C-O-C); 1H-NMR (DMSO-d6) δ: 3.90 (s, 
3H, OCH3), 7.14-7.16 (d, 2H, H2’+H6’, J2’3’/J6’5’=8.68 Hz), 8.01-8.05 (d, 1H, Hb, Jba=16.03 Hz), 8.22-8.24 (d, 2H, 
H3’+H5’, J3’2’/J5’6’=8.63 Hz), 8.51-8.63 (m, 3H, Ha+H5+H8), 9.59 (s, 1H, H3); Analysis calculated for C18H12N2O4F2 
(358.30): C, 60.34; H, 3.38; N, 7.82. Found: C, 60.07; H, 3.35; N, 7.65. 
General method for the synthesis of (2E)-1-(3-Methyl-quinoxalin-2-yl)-3-(3,4,5-trimethoxy-phenyl)-propenone 
derivatives (Series 6). The synthesis of compounds 6 was carried out as shown in Scheme 2. The starting reagents 
used (VII and VIII) were obtained by means of previously described methods.23,24 To a solution of 1-(3-Methyl-
quinoxalin-2-yl)-ethanone derivative VIII (1 mmol) and 3,4,5-Trimethoxy-benzaldehyde (1 mmol) in methanol, a 
solution of 3% NaOH in methanol (1 mL) was added. After 24 hours, the reaction mixture was filtered and the solid 
washed with water. 
(2E)-1-(3-Methyl-quinoxalin-2-yl)-3-(3,4,5-trimethoxy-phenyl)-propenone (6a). The derivative 6a was obtained 
as yellow solid (56%). IR (KBr) 1666 (C=O), 1133 (C-O-C); 1H-NMR (CDCl3) δ: 3.01 (s, 3H, CH3), 3.94 (s, 3H, p-
OCH3), 3.95 (s, 6H, m-OCH3), 6.94 (s, 2H, H2’+H6’), 7.75-7.79 (d, 1H, Ha, Jab=16.02 Hz), 7.81-7.90 (m, 2H, H6+H7), 
7.84-7.88 (d, 1H, Hb, Jba=15.94 Hz), 8.09-8.11 (d, 1H, H5, J56=8.31 Hz), 8.20-8.22 (d, 1H, H8, J87=8.30 Hz); Analysis 
calculated for C21H20N2O4 (364.40): C, 69.23; H, 5.49; N, 7.69. Found: C, 69.46; H, 5.53; N, 7.45. 
(2E)-1-(7-Fluoro-3-methyl-quinoxalin-2-yl)-3-(3,4,5-trimethoxy-phenyl)-propenone (6b). The compound 6b was 
obtained as yellow solid (59%). IR (KBr) 1670 (C=O), 1128 (C-O-C); 1H-NMR (CDCl3) δ: 2.98 (s, 3H, CH3), 3.94 
(s, 3H, p-OCH3), 3.95 (s, 6H, m-OCH3), 6.93 (s, 2H, H2’+H6’), 7.63-7.68 (ddd, 1H, H6, J65=9.26 Hz, J6F=8.12 Hz, 
J68=2.83 Hz), 7.74-7.78 (d, 1H, Ha, Jab=15.98 Hz), 7.79-7.83 (d, 1H, Hb, Jba=15.97 Hz), 7.82-7.85 (dd, 1H, H8, 
J8F=8.84 Hz, J86=2.78 Hz), 8.09-8.12 (dd, 1H, H5, J56=9.25 Hz, J5F=5.60 Hz); Analysis calculated for C21H19N2O4F 
(382.39): C, 65.97; H, 4.97; N, 7.33. Found: C, 66.13; H, 5.04; N, 7.11. 
(2E)-1-(7-Methoxy-3-methyl-quinoxalin-2-yl)-3-(3,4,5-trimethoxy-phenyl)-propenone (6c). The derivative 6c 
was obtained as yellow solid (31%). IR (KBr) 1670 (C=O), 1126 (C-O-C); 1H-NMR (CDCl3) δ: 2.97 (s, 3H, CH3), 
3.94 (s, 3H, p-OCH3), 3.95 (s, 6H, m-OCH3), 4.02 (s, 3H, quinox-OCH3), 6.93 (s, 2H, H2’+H6’), 7.47-7.48 (d, 1H, H8, 
J86=2.61 Hz), 7.51-7.54 (dd, 1H, H6, J65=9.17 Hz, J68=2.75 Hz), 7.73-7.77 (d, 1H, Ha, Jab=16.00 Hz), 7.80-7.84 (d, 
1H, Hb, Jba=15.98 Hz), 7.99-8.02 (d, 1H, H5, J56=9.17 Hz); Analysis calculated for C22H22N2O5 (394.43): C, 67.00; H, 
5.58; N, 7.11. Found: C, 67.08; H, 5.61; N, 7.05. 
(2E)-1-(7-Chloro-3-methyl-quinoxalin-2-yl)-3-(3,4,5-trimethoxy-phenyl)-propenone (6d). The derivative 6d was 
obtained as yellow solid (31%). IR (KBr) 1670 (C=O), 1128 (C-O-C); 1H-NMR (CDCl3) δ: 2.99 (s, 3H, CH3), 3.94 
(s, 3H, p-OCH3), 3.96 (s, 6H, m-OCH3), 6.93 (s, 2H, H2’+H6’), 7.74-7.78 (d, 1H, Ha, Jab=16.00 Hz), 7.79-7.83 (d, 1H, 
Hb, Jba=15.98 Hz), 7.79-7.82 (dd, 1H, H6, J65=8.93 Hz, J68=2.26 Hz), 8.03-8.05 (d, 1H, H5, J56=8.96 Hz), 8.21-8.22 
(d, 1H, H8, J86=2.21 Hz); Analysis calculated for C21H19N2O4Cl (398.85): C, 63.24; H, 4.77; N, 7.03. Found: C, 
62.92; H, 4.89; N, 6.73. 
(2E)-1-(3,7-Dimethyl-quinoxalin-2-yl)-3-(3,4,5-trimethoxy-phenyl)-propenone (6e). The compound 6e was 
obtained as yellow solid (49%). IR (KBr) 1670 (C=O), 1126 (C-O-C); 1H-NMR (CDCl3) δ: 2.64 (s, 3H, 7-CH3), 3.00 
(s, 3H, 3-CH3), 3.94 (s, 3H, p-OCH3), 3.95 (s, 6H, m-OCH3), 6.93 (s, 2H, H2’+H6’), 7.69-7.72 (dd, 1H, H6, J65=8.55 
Hz, J68=1.76 Hz), 7.74-7.78 (d, 1H, Ha, Jab=15.99 Hz), 7.85-7.89 (d, 1H, Hb, Jba=15.94 Hz), 7.98 (s, 1H, H8), 7.99-
8.01 (d, 1H, H5, J56=8.75 Hz); Analysis calculated for C22H22N2O4 (378.43): C, 69.84; H, 5.82; N, 7.41. Found: C, 
69.92; H, 5.79; N, 7.48. 
(2E)-3-(3,4,5-Trimethoxy-phenyl)-1-(3,6,7-trimethyl-quinoxalin-2-yl)-propenone (6f). The compound 6f was 
obtained as yellow solid (38%). IR (KBr) 1671 (C=O), 1127 (C-O-C); 1H-NMR (CDCl3) δ: 2.55 (s, 3H, 6/7-CH3), 
2.56 (s, 3H, 6/7-CH3), 3.01 (s, 3H, 3-CH3), 3.94 (s, 3H, p-OCH3), 3.96 (s, 6H, m-OCH3), 6.94 (s, 2H, H2’+H6’), 7.75-
7.79 (d, 1H, Ha, Jab=15.96 Hz), 7.89 (s, 1H, H8), 7.89-7.93 (d, 1H, Hb, Jba=15.95 Hz), 7.96 (s, 1H, H5); Analysis 
calculated for C23H24N2O4 (392.46): C, 70.41; H, 6.12; N, 7.14. Found: C, 70.34; H, 6.12; N, 7.00. 
General method for the synthesis of 4-(3-Methyl-quinoxalin-2-yl)-6-(3,4,5-trimethoxy-phenyl)-pyrimidin-2-
ylamine derivatives (Series 7). To a solution of the corresponding compound of series 6 (0.5 mmol) and guanidine 
hydrochloride (1 mmol) in isopropanol, 0.56 mL of a solution 10% KOH in isopropanol were added. The reaction 
mixture was refluxing over 24 hours. The solvent was removed under reduced pressure and the crude residue was 
purified by flash chromatography using hexane:ethyl acetate (50:50) to yield compounds 7. 
4-(3-Methyl-quinoxalin-2-yl)-6-(3,4,5-trimethoxy-phenyl)-pyrimidin-2-ylamine (7a). The derivative 7a was 
obtained as beige solid (15%). IR (KBr) 3432-3346 (N-H), 1620 (C=N), 1126 (C-O-C); 1H-NMR (DMSO-d6) δ: 2.84 
(s, 3H, CH3); 3.75 (s, 3H, p-OCH3); 3.88 (s, 6H, m-OCH3); 6.96 (s, 2H, NH2); 7.48 (s, 2H, H2’+H6’); 7.65 (s, 1H, ar-
CH); 7.84-7.92 (m, 2H, H6+H7); 8.08-8.11 (dd, 1H, H8, J87=8.24 Hz; J86=1.22 Hz); 8.15-8.17 (d, 1H, H5, J56=8.27 
Hz); Analysis calculated for C22H21N5O3 (403.44): C, 65.51; H, 5.21; N, 17.37. Found: C, 65.59; H, 5.45; N, 17.48. 
4-(7-Fluoro-3-methyl-quinoxalin-2-yl)-6-(3,4,5-trimethoxy-phenyl)-pyrimidin-2-ylamine (7b). The compound 
7b was obtained as beige solid (15%). IR (KBr) 3430-3308 (N-H), 1628 (C=N), 1133 (C-O-C); 1H-NMR (DMSO-d6) 
δ: 2.83 (s, 3H, CH3); 3.74 (s, 3H, p-OCH3); 3.88 (s, 6H, m-OCH3); 6.98 (s, 2H, NH2); 7.47 (s, 2H, H2’+H6’); 7.65 (s, 
1H, ar-CH); 7.81-7.86 (ddd, 1H, H6, J65=9.13 Hz; J6F=8.86 Hz; J68=2.81 Hz); 7.94-7.97 (dd, 1H, H8, J8F=9.37 Hz; 
J86=2.78 Hz); 8.16-8.20 (dd, 1H, H5, J56=9.23 Hz; J5F=5.84 Hz); Analysis calculated for C22H20FN5O3 (421.43): C, 
62.71; H, 4.75; N, 16.63. Found: C, 62.30; H, 5.15; N, 16.40. 
4-(7-Methoxy-3-methyl-quinoxalin-2-yl)-6-(3,4,5-trimethoxy-phenyl)-pyrimidin-2-ylamine (7c). The derivative 
7c was obtained as beige solid (9%). IR (KBr) 3458-3212 (N-H), 1620 (C=N), 1127 (C-O-C); 1H-NMR (DMSO-d6) 
δ: 2.79 (s, 3H, CH3); 3.74 (s, 3H, p-OCH3); 3.88 (s, 6H, m-OCH3); 3.96 (s, 3H, 7-OCH3); 6.94 (s, 2H, NH2); 7.48 (s, 
2H, H2’+H6’); 7.51-7.54 (m, 2H, H6+H8); 7.63 (s, 1H, ar-CH); 7.97-8.00 (d, 1H, H5, J56=9.92 Hz); Analysis 
calculated for C23H23N5O4 (433.47): C, 63.74; H, 5.31; N, 16.17. Found: C, 63.35; H, 5.39; N, 15.99. 
4-(7-Chloro-3-methyl-quinoxalin-2-yl)-6-(3,4,5-trimethoxy-phenyl)-pyrimidin-2-ylamine (7d). The derivative 7d 
was obtained as beige solid (10%). IR (KBr) 3447-3308 (N-H), 1630 (C=N), 1132 (C-O-C); 1H-NMR (DMSO-d6) δ: 
2.84 (s, 3H, CH3); 3.74 (s, 3H, p-OCH3); 3.88 (s, 6H, m-OCH3); 6.99 (s, 2H, NH2); 7.47 (s, 2H, H2’+H6’); 7.65 (s, 
1H, ar-CH); 7.91-7.94 (dd, 1H, H6, J65=8.93 Hz; J68=2.38 Hz); 8.12-8.14 (d, 1H, H5, J56=8.95 Hz); 8.26-8.27 (d, 1H, 
H8, J86=2.26 Hz); Analysis calculated for C22H20ClN5O3 (437.89): C, 60.34; H, 4.57; N, 16.00. Found: C, 60.22; H, 
4.72; N, 15.66. 
4-(3,7-Dimethyl-quinoxalin-2-yl)-6-(3,4,5-trimethoxy-phenyl)-pyrimidin-2-ylamine (7e). The derivative 7e was 
obtained as beige solid (13%). IR (KBr) 3458-3360 (N-H), 1616 (C=N), 1129 (C-O-C); 1H-NMR (DMSO-d6) δ: 2.58 
(s, 3H, 7-CH3); 2.81 (s, 3H, 3-CH3); 3.74 (s, 3H, p-OCH3); 3.88 (s, 6H, m-OCH3); 6.96 (s, 2H, NH2); 7.47 (s, 2H, 
H2’+H6’); 7.63 (s, 1H, ar-CH); 7.72-7.74 (d, 1H, H6, J65=8.57 Hz); 7.93 (s, 1H, H8); 7.97-7.99 (d, 1H, H5, J56=8.58 
Hz); Analysis calculated for C23H23N5O3 (417.47): C, 66.19; H, 5.52; N, 16.79. Found: C, 65.93; H, 5.61; N, 16.66. 
General method for the synthesis of 2-methyl-3-[5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-
quinoxaline derivatives (Series 8) and of 2-Methoxy-4-[5-(3-methyl-1,4-dioxy-quinoxalin-2-yl)-3,4-dihydro-2H-
pyrazol-3-yl]-phenol derivatives (Series 10). 2 mmol of hydrazine hydrate 98% were added to a solution of 0,5 
mmol of the appropriate compound of series 6 in absolute ethanol. After 24 hours, the dissolvent was removed under 
reduced pressure and the solid obtained (compound of series 8) was filtered and washed with ethyl ether. In the same 
way, 2 mmol of hydrazine hydrate 98% were added to a solution of 1 mmol of the corresponding series 2 derivative 
and the reaction mixture was stirred for 24 hours. After removing the solvent under reduced pressure the residue was 
precipitated with ethyl acetate and the solid obtained (compounds of series 10) was filtered. 
6-Methoxy-2-methyl-3-[5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-quinoxaline (8c). The 
derivative 8c was obtained as yellow solid (74%). IR (KBr) 3206 (N-H), 1592 (C=N), 1127 (C-O-C); 1H-NMR 
(DMSO-d6) δ: 2.92 (s, 3H, CH3); 3.10-3.17 (dd, 1H, HA, upfield H of CH2, JAB=16.67 Hz; JAX=10.64 Hz); 3.65 (s, 
3H, p-OCH3); 3.68-3.74 (dd, 1H, HB, downfield H of CHB 2, JBA=16.76 Hz; JBX=11.30 Hz); 3.78 (s, 6H, m-OCH3); 
3.92 (s, 3H, q-OCH3); 4.89-4.95 (ddd, 1H, HX, CH, JXA=10.98 Hz; JXB=11.06 Hz; JX-NH=2.10 Hz); 6.72 (s, 2H, 
H2’+H6’); 7.28-7.29 (d, 1H, H8, J86=2.76 Hz); 7.37-7.40 (dd, 1H, H6, J65=9.12 Hz; J68=2.80 Hz); 7.85-7.87 (d, 1H, 
H5, J56=9.11 Hz); 8.53 (d, 1H, NH, JNH-X=2.13 Hz); Analysis calculated for C22H24N4O4 (408.46): C, 64.71; H, 5.88; 
N, 13.73. Found: C, 64.26; H, 5.72; N, 13.59. 
2,6,7-Trimethyl-3-[5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-quinoxaline (8f). The derivative 8f 
was obtained as yellow solid (74%). IR (KBr) 3205 (N-H), 1589 (C=N), 1128 (C-O-C); 1H-NMR (DMSO-d6) δ: 
2.43-2.44 (2s, 6H, 6-CH3+7-CH3); 2.92 (s, 3H, 3-CH3); 3.07-3.14 (dd, 1H, HA, upfield H of CH2, JAB=16.51 Hz; 
JAX=11.05 Hz); 3.65 (s, 3H, p-OCH3); 3.69-3.73 (m, 1H, HB, downfield H of CHB 2); 3.78 (s, 6H, m-OCH3); 4.87-4.92 
(t, 1H, HX, CH, JXA=10.56 Hz; JXB=10.56 Hz); 6.73 (s, 2H, H2’+H6’); 7.71-7.73 (2s, 2H, H5+H8); 8.42 (s, 1H, NH); 
Analysis calculated for C23H26N4O3 (406.49): C, 67.98; H, 6.40; N, 13.79. Found: C, 67.65; H, 6.92; N, 13.63. 
2-Methoxy-4-[5-(3-methyl-1,4-dioxy-quinoxalin-2-yl)-3,4-dihydro-2H-pyrazol-3-yl]-phenol (10a). The derivative 
10a was obtained as yellow solid (35%). IR (KBr) 3537-3317 (N-H, O-H), 1606 (C=N), 1331 (N-O), 1273 (C-O); 
1H-NMR (DMSO-d6) δ: 2.60 (s, 3H, CH3); 3.16-3.22 (m, 1H, HA, upfield H of CH2); 3.46-3.53 (dd, 1H, HB, 
downfield H of CH
B
2, JBA=16.23 Hz; JBX=11.20 Hz); 3.79 (s, 3H, OCH3); 4.88-4.93 (m, 1H, HX, CH); 6.74-6.77 (dd, 
1H, H6’, J6’5’=8.03Hz; J6’2’=1.42Hz); 6.84-6.86 (m, 1H, H5’); 7.06 (s, 1H, H2’); 7.91-7.98 (m, 2H, H6+H7); 8.11 (s, 
1H, NH); 8.46-8.51 (m, 2H, H5+H8); 8.92 (s, 1H, OH); Analysis calculated for C19H18N4O4 (366.38): C, 62.30; H, 
4.92; N, 15.30. Found: C, 62.24; H, 5.18; N, 14.90. 
General method for the synthesis of 4-[3-(3-Methyl-quinoxalin-2-yl)-5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-
pyrazol-1-yl]-benzenesulfonamide derivatives (Series 9). The corresponding compound of series 6 (0,55 mmol), 4-
hydrazinobenzene-1-sulfonamide hydrochloride 97% (0,55 mmol) and 10 mL of ethanol 99% were mixed in a 
microwave reaction flask. The program (50 W, 5’) was carried out four times. The solid obtained was filtered and 
purified by flash column chromatography using ethyl acetate to yield compounds of series 9. 
4-[3-(3-Methyl-quinoxalin-2-yl)-5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-pyrazol-1-yl]-benzenesulfonamide 
(9a). The derivative 9a was obtained as yellow solid (14%). IR (KBr) 3337-3248 (N-H), 1594 (C=N), 1341 (as 
O=S=O), 1158 (sym O=S=O), 1129 (C-O-C); 1H-NMR (acetone-d6) δ: 3.20 (s, 3H, CH3); 3.63-3.57 (dd, 1H, HA, 
upfield H of CH2, JAB=18.10 Hz; JAX=6.18 Hz); 3.71 (s, 3H, p-OCH3); 3.78 (s, 6H, m-OCH3); 4.22-4.30 (dd, 1H, HB, 
downfield H of CH
B
2, JBA=18.11 Hz; JBX=12.44 Hz); 5.63-5.68 (dd, 1H, HX, CH, JXA=6.15 Hz; JXB=12.44 Hz); 6.36 
(s, 2H, NH2); 6.75 (s, 2H, H2’+H6’); 7.31-7.34 (d, 2H, HC, JCD=8.96 Hz); 7.75-7.83 (d, 2H, HD, JDC= 8.97 Hz); 7.79-
7.83 (m, 2H, H6+H7); 7.99-8.03 (m, 2H, H5+H8); Analysis calculated for C27H27N5O5S (533.61): C, 60.79; H, 5.07; 
N, 13.13. Found: C, 60.68; H, 5.22; N, 12.70. 
4-[3-(7-Fluoro-3-methyl-quinoxalin-2-yl)-5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-pyrazol-1-yl]-
benzenesulfonamide (9b). The derivative 9b was obtained as yellow solid (29%). IR (KBr) 3306-3243 (N-H), 1594 
(C=N), 1330 (as O=S=O), 1160 (sym O=S=O), 1130 (C-O-C); 1H-NMR (acetone-d6) δ: 3.19 (s, 3H, CH3); 3.55-3.61 
(dd, 1H, HA, upfield H of CH2, JAB=18.10 Hz; JAX=6.20 Hz); 3.71 (s, 3H, p-OCH3); 3.78 (s, 6H, m-OCH3); 4.21-4.29 
(dd, 1H, HB, downfield H of CHB 2, JBA=18.09 Hz; JBX=12.47 Hz); 5.65-5.70 (dd, 1H, HX, CH, JXA=6.05 Hz; 
JXB=12.37 Hz); 6.36 (s, 2H, NH2); 6.74 (s, 2H, H2’+H6’); 7.32-7.35 (d, 2H, HC, JCD=8.96 Hz); 7.63-7.69 (m, 2H, 
H6+H8); 7.75-7.79 (d, 2H, HD, JDC= 9.06 Hz); 8.06-8.10 (d, 1H, H5, J56=9.99 Hz; J5F=5.80 Hz); Analysis calculated 
for C27H26FN5O5S (551.60): C, 58.80; H, 4.72; N, 12.70. Found: C, 58.56; H, 4.76; N, 12.32. 
4-[3-(7-Methoxy-3-methyl-quinoxalin-2-yl)-5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-pyrazol-1-yl]-
benzenesulfonamide (9c). The derivative 9c was obtained as yellow solid (9.5%). IR (KBr) 3313-3229 (N-H), 1593 
(C=N), 1326 (as O=S=O), 1155 (sym O=S=O), 1122 (C-O-C); 1H-NMR (DMSO-d6) δ: 3.10 (s, 3H, CH3); 3.44-3.50 
(dd, 1H, HA, upfield H of CH2, JAB=17.75 Hz; JAX=5.51 Hz); 3.62 (s, 3H, p-OCH3); 3.70 (s, 6H, m-OCH3); 3.92 (s, 
3H, q-OCH3); 4.10-4.18 (dd, 1H, HB, downfield H of CHB 2, JBA=18.17 Hz; JBX=12.31 Hz); 5.61-5.65 (dd, 1H, HX, 
CH, JXA=5.56 Hz; JXB=12.38 Hz); 6.90 (s, 2H, H2’+H6’); 7.13 (s, 2H, NH2); 7.22-7.24 (d, 2H, HC, JCD=8.55 Hz); 
7.32-7.33 (d, 1H, H8, J86=2.47 Hz); 7.43-7.46 (dd, 1H, H6, J65=8.83 Hz; J68=2.37 Hz); 7.68-7.71 (d, 2H, HD, JDC= 
8.70 Hz); 7.91-7.93 (d, 1H, H5, J56=9.07 Hz); Analysis calculated for C28H29N5O6S (563.64): C, 59.68; H, 5.15; N, 
12.43. Found: C, 59.20; H, 4.96; N, 12.07. 
4-[3-(7-Chloro-3-methyl-quinoxalin-2-yl)-5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-pyrazol-1-yl]-
benzenesulfonamide (9d). The derivative 9d was obtained as yellow solid (12%). IR (KBr) 3302-3225 (N-H), 1594 
(C=N), 1341 (as O=S=O), 1157 (sym O=S=O), 1130 (C-O-C); 1H-NMR (DMSO-d6) δ: 3.14 (s, 3H, CH3); 3.40-3.46 
(dd, 1H, HA, upfield H of CH2, JAB=17.80 Hz; JAX=6.01 Hz); 3.62 (s, 3H, p-OCH3); 3.70 (s, 6H, m-OCH3); 4.09-4.17 
(dd, 1H, HB, downfield H of CHB 2, JBA=17.91 Hz; JBX=12.41 Hz); 5.63-5.67 (dd, 1H, HX, CH, JXA=5.83 Hz; 
JXB=12.21 Hz); 6.61 (s, 2H, H2’+H6’); 7.13 (s, 2H, NH2); 7.24-7.26 (d, 2H, HC, JCD=8.91 Hz); 7.69-7.71 (d, 2H, HD, 
JDC= 8.95 Hz); 7.81-7.84 (dd, 1H, H6, J65=8.94 Hz; J68=2.28 Hz); 8.03-8.04 (d, 1H, H8, J86=2.45 Hz); 8.03-8.05 (d, 
1H, H5, J56=8.72 Hz); Analysis calculated for C27H26ClN5O5S (568.06): C, 57.09; H, 4.58; N, 12.33. Found: C, 56.68; 
H, 4.62; N, 11.97. 
Biological Experiments 
Experiments in vitro 
In the in vitro assays each experiment was performed at least in triplicate and the standard deviation of absorbance 
was less than 10 % of the mean. 
Determination of the reducing activity of the stable radical 1,1-diphenyl-picrylhydrazyl (DPPH)33. To a 
solution of DPPH in absolute ethanol an equal volume of the compounds dissolved in DMSO was added. An ethanol 
solution was used as control. The concentrations of the solutions of the compounds were 0.05mM, 0.1 and 0.2mM. 
After 20 and 60 min at room temperature the absorbance was recorded at 517nm. 
ABTS+• - Decolorization assay in ethanolic solution for antioxidant activity26. ABTS is dissolved in water to a 7 
mM concentration. ABTS radical cation (ABTS+•) produced by reacting ABTS stock solution with 2.45 mM 
potassium persulfate (final concentration) and allowing the mixture to stand in the dark at room temperature for 12–
16 h before use. For the present study, the ABTS+• solution  was  diluted with ethanol to an absorbance of 0.70 
(60.02) at 734 nm and equilibrated at 30°C. Stock solutions of the tested compounds in DMSO were diluted so that, 
after introduction of a 10-ml aliquot of each dilution into the assay, they produced between 20%–80% inhibition of 
the blank absorbance. After addition of 1.0 ml of diluted ABTS+• solution (A734nm) to 10 μl of antioxidant 
compounds or Trolox standards (final concentration 0.1 mM) in ethanol the absorbance reading was taken at room 
temperature exactly 1 min after the initial mixing. 
Non enzymatic assay of superoxide radicals-Measurement of superoxide radical scavenging activity33. The 
superoxide producing system was set up by mixing PMS, NADH and air –oxygen. The production of superoxide was 
estimated by the nitroblue tetrazolium method. The reaction mixture containing compounds, 3 μM PMS, 78 μM 
NADH, and 25 μM NBT in 19 μM phosphate buffer pH 7.4 was incubated for 2 min at room temperature and the 
absorption measured at 560 nm against a blank containing PMS. The tested compounds were preincubated for 2 min 
before adding NADH. 
Competition of the tested compounds with DMSO for hydroxyl radicals33. The hydroxyl radicals generated by 
the Fe 3+ /ascorbic acid system, were detected according to Nash, by the determination of formaldehyde produced 
from the oxidation of DMSO. The reaction mixture contained EDTA (0.1 mM), Fe 3+ (167 μM), DMSO (33 mM) in 
phosphate buffer (50 mM, pH 7.4), the tested compounds (concentration 0.1mM) and ascorbic acid (10 mM). After 
30 min of incubation (37o C) the reaction was stopped with CCl3COOH (17 % w/v) 
Inhibition of linoleic acid lipid peroxidation31. Ten microliters of the 16 mM linoleic acid dispersion was added to 
the UV cuvette containing 0.93 mL of 0.05 M phosphate buffer, pH 7.4 prethermostated at 37°C. The oxidation 
reaction was initiated at 37 °C under air by the addition of 50 μL of 40 mM AAPH solution. Oxidation was carried 
out in the presence of aliquots in different concentrations. In the assay without antioxidant, lipid oxidation was 
measured in the presence of the same level of DMSO. The rate of oxidation at 37ºC was monitored by recording the 
increase in absorption at 234 nm caused by conjugated diene hydroperoxides 
Soybean lipoxygenase inhibition study in vitro. In vitro study was evaluated as reported previously.33 The tested 
compounds dissolved in DMSO were incubated at room temperature in different concentrations with sodium linoleate 
(0.1 mM) and 0.2 ml of enzyme solution (1/9 x 10-4 w/v in saline). The conversion of sodium linoleate to 13-
hydroperoxylinoleic acid at 234 nm was recorded and compared with the appropriate standard inhibitor. IC50 values 
were determined. 
Experiments in vivo 
Inhibition of the carrageenin-induced edema. Edema was induced in the right hind paw of Fisher 344 rats (150-
200 g) by the intradermal injection of 0.1 ml 2% carrageenin in water. Both sexes were used. Females pregnant were 
excluded. Each group was composed of 6-15 animals. The animals, which have been bred in our laboratory, were 
housed under standard conditions and received a diet of commercial food pellets and water ad libitum during the 
maintenance but they were entirely fasted during the experiment period. Our studies were in accordance with 
recognised guidelines on animal experimentation. 
The tested compounds 0.01 mmol/kg body weight, were suspended in water, with few drops of Tween 80 and 
ground in a mortar before use and were given intraperitoneally simultaneously with the carrageenin injection. The 
rats were euthanized 3.5 h after carrageenin injection. The difference between the weight of the injected and 
uninjected paws was calculated for each animal. The change in paw weight was compared with that in control 
animals (treated with water) and expressed as a percent inhibition of the edema CPE % values. Indomethacin in 0.01 
mmol/kg presented 47%  inhibition of the edema. Values CPE % are the mean from two different experiments with a 
standard error of the mean less than 10 %. 
Conclusions 
Several new quinoxaline and quinoxaline 1,4-di-N-oxide derivatives have been synthesized with the aim of 
studying their antioxidant and anti-inflammatory activities. We have optimized the synthesis of some of these 
derivatives by using microwave assisted methods that greatly improved reaction times and conversion ratios. 
In terms of biological activity, the most interesting derivatives were those with the pyrazoline moiety (series 3, 8 
and 10) and among them, those with N-oxide groups in the quinoxaline ring (series 3 and 10) exhibited significantly 
increased reducing activity compared to their reduced analogues (series 8). Compounds with an α,β-unsaturated 
ketone system (1b, 2e, 4f, 5a, 5b, 5g and 6a-f) presented the best superoxide scavenging activities being the reduced 
derivatives (6a-f) the most interesting structures with interaction values between 79 and 100 %. This evidence led us 
to affirm that the olefinic moiety might play an important role in the activity of these compounds by trapping the 
superoxide radical. The derivatives are good hydroxyl radical scavengers. Compounds 6b and 6e were the best 
inhibitors of lipid peroxidation displaying IC50 values of 0.01 mM and <0.01 mM respectively. In general, 
compounds that displayed good activities as inhibitors of lipid peroxidation also presented good values of inhibition 
of LOX. Compound 7b showed significant protection against carragenin induced paw edema. 
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